Go Pro
OTCMKTS:GTHP

Guided Therapeutics Q1 2026 Earnings Report

Guided Therapeutics logo
$0.28 +0.01 (+3.67%)
As of 12:35 PM Eastern

Guided Therapeutics EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Guided Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Guided Therapeutics Announcement Details

Quarter
Q1 2026
Time
During Market Hours
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Guided Therapeutics Earnings Headlines

BlackRock, JPMorgan, and Goldman are all stock piling the same asset… are you?
BlackRock, JPMorgan, Goldman Sachs, Fidelity, ARK Invest and Andreessen Horowitz are all buying the same asset. The reason is tied to a legal mandate - the Clarity Act now requires the entire $382 trillion financial system to move onto a new monetary infrastructure by April 2027. BlackRock CEO Larry Fink calls it 'the next major evolution in market infrastructure.' Every transaction on this new grid burns one specific scarce digital resource - and institutions are accumulating shares before prices move.tc pixel
See More Guided Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Guided Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Guided Therapeutics and other key companies, straight to your email.

About Guided Therapeutics

Guided Therapeutics (OTCMKTS:GTHP), Inc. is a medical device company focused on the development and commercialization of non‐invasive optical diagnostic platforms for women’s health. Its flagship product, the LuViva® Advanced Cervical Scan, combines hyperspectral and reflectance imaging to support the early detection of cervical epithelial abnormalities. By capturing tissue fluorescence and reflectance signatures in real time, LuViva is designed to augment traditional visual inspection methods and assist clinicians during colposcopic evaluations.

The company secured 510(k) clearance from the U.S. Food and Drug Administration in 2013 and obtained CE marking for distribution within the European Union, enabling it to market its technology across multiple regions. Guided Therapeutics collaborates with academic and research institutions—including the National Cancer Institute—to validate its imaging algorithms through clinical studies conducted in both the United States and Europe. These partnerships have informed ongoing refinements to the LuViva platform and supported expansion of its distribution channels via direct sales and strategic alliances.

Founded in 1993 and headquartered in Melbourne, Florida, Guided Therapeutics leverages a multidisciplinary management team with expertise in biomedical engineering, oncology, and regulatory affairs. Building on the core technology behind LuViva, the company is exploring additional applications in gynecologic and dermatologic diagnostics. Its long-term strategy aims to extend its non‐invasive optical imaging capabilities to address a broader range of clinical needs in early disease detection.

View Guided Therapeutics Profile